CSL Biotherapies today reported findings detailing how young children may be at risk of suffering convulsions related to fever (febrile seizures) after receiving the Fluvax flu vaccine.
In 2010, reports of unexpected adverse events in children who had received the Fluvax vaccine emerged, and CSL investigated the cause. Specifically, Fluvax® was associated with increased reports of fever-related (febrile) convulsions in children compared to previous seasons. The convulsions occurred predominantly in children under the age of 5 years, shortly after vaccination. Since then, Fluvax has not been licensed for children under 5.
The findings were reported at the Public Health Association of Australia’s 13th National Immunisation Conference in Darwin. The preliminary conclusions have been drawn from a comprehensive two year investigation that has been monitored by the Therapeutic Goods Administration (TGA) and the Food & Drug Administration (FDA).
For more information about the study, click here.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.